Shanghai INT Medical buys 100% of Shanghai Maoyi for US$55.12 million, lifting Valgen stake to 27.82%

• Shanghai INT Medical Instruments agreed to buy 100% of Shanghai Maoyi partnership interests for US$ 55.12 million, settling in cash in RMB.
• Shanghai Maoyi indirectly holds 579,866 series B preferred shares in Valgen Holding, equal to about 3.85% of its issued share capital.
• The deal implies about US$ 95.06 per underlying series B preferred share.
• Combined with earlier purchases in 2026, INT’s stake in Valgen would rise to 4,193,775 shares, about 27.82%.
• Valgen reported 2025 revenue of RMB 205.88 million, profit before tax of RMB 49.57 million, total assets of RMB 691.61 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Int Medical Instruments Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260723-12254799), on July 23, 2026, and is solely responsible for the information contained therein.